Knowledge (XXG)

3,4-Ethylidenedioxyamphetamine

Clinical data
ATC code	none
Legal status
Legal status	CA: Schedule I DE: NpSG (Industrial and scientific use only) UK: Class A
Identifiers
IUPAC name 1-(2-Methyl-1,3-benzodioxol-5-yl)propan-2-amine
CAS Number	125299-84-5
PubChem CID	130542
ChemSpider	115478
UNII	T927DM865T
CompTox Dashboard (EPA)	DTXSID401029691
Chemical and physical data
Formula	C11H15NO2
Molar mass	193.246 g·mol
3D model (JSmol)	Interactive image
SMILES CC(N)Cc2ccc1OC(C)Oc1c2
InChI InChI=1S/C11H15NO2/c1-7(12)5-9-3-4-10-11(6-9)14-8(2)13-10/h3-4,6-8H,5,12H2,1-2H3 Key:SLXACJFRFCJPAH-UHFFFAOYSA-N
(verify)

3,4-Ethylidenedioxyamphetamine (EIDA) is a substituted derivative of 3,4-methylenedioxyamphetamine (MDA), which was developed by David Nichols and coworkers, in the course of research to determine the bulk tolerance around the benzodioxole portion of the MDA molecule. EIDA was found to produce similar effects to MDA in animals but with less than half the potency, while the isopropylidenedioxy derivative (IPIDA, IDA) did not substitute for MDA and instead had sedative and convulsant effects. This shows limited bulk tolerance at this position and (as with 2C-G-5) makes it likely the activity of EIDA will reside primarily in one enantiomer, although only the racemic mix has been studied as yet.

• DiFMDA
• EDMA
• F-2 (psychedelic)

• Drugs not assigned an ATC code
• Substituted amphetamines
• Entactogens and empathogens
• Benzodioxoles